TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01808261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK249320 100/mg
Description: Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
Study: NCT05620615

Intervention type: OTHER
Intervention: Intensive Drug Therapy
Description: Observational only and no predesigned interventions in this study
Study: NCT03026959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The mindfulness intervention follows the structure described by Short, Mazmanian, Ozen, \& Bédard, (2015).
Study: NCT00287729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
Study: NCT05437445

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma amino acid assay
Description: Plasma amino acid analysis was performed on all the blood samples received in biogenetics lab at Aga khan university, Karachi during one year period.
Study: NCT00665483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Prick Test
Description: Skin Prick Test
Study: NCT02916134

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic +/- Open Appendicectomy
Description: Laparoscopic +/- open appendicectomy , with antibiotics at induction (intravenous co-amoxiclav 1.2g, or if penicillin allergic, cefuroxime 1.5g + metronidazole 500mg ), followed by 3 further intravenous doses of the same antibiotic. If a perforation is identified at the time of surgery, microbiology will be contacted regarding choice and duration of of antibiotic.
Study: NCT00806481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate
Description: Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment group: treatment with tablets of placebo three times daily for 36 weeks
Study: NCT02916134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Description: Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.~The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics.
Study: NCT01537380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazoline
Description: Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
Study: NCT02728817

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: End-cephalic vein to side-radial artery fistula creation
Description: * Circumferential dissection of the cephalic vein (4-5cm long)~* Longitudinal arteriotomy (\~10mm)~* End-vein to side-artery anastomosis using 7-0 polypropylene continuous suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RADAR fistula creation
Description: * Dissection of the anterior-medial aspect of the cephalic vein (\~15mm) without grasping or clamping the venous wall~* Circumferential dissection of the radial artery pedicle (5cm long) and ligation of collaterals with surgical microclips~* Ligation and section of the radial artery (distal)~* Longitudinal venotomy (\~10mm)~* End-artery to side-vein anastomosis using 7-0 polypropylene continuous suture
Study: NCT02450838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V180
Description: Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V180
Description: Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel™
Description: Aluminum hydroxide gel adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04319926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine topical system 1.8%
Description: One topical system is applied to the subject's back for 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine topical system 1.8%
Description: One topical system is applied to the subject's back for 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch 5%
Description: One generic lidocaine patch is applied to the subject's back for 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch 5%
Description: One generic lidocaine patch is applied to the subject's back for 12 hours.
Study: NCT02532283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered placebo tablets orally twice daily for 7 days.
Study: NCT04553055

Intervention type: OTHER
Intervention: online questionnaires
Description: questionnaire (with detailed questions including how/when/which/for how long antibiotics are prescribed)
Study: NCT01217788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH94B intranasal spray
Description: Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PH94B intranasal spray
Description: Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
Study: NCT01835353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 100mg loading dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 60mg loading dose
Description: Prasugrel 60mg loading dose
Study: NCT03388476

Intervention type: DIAGNOSTIC_TEST
Intervention: Capnography
Description: Measuring of the exhaled air, especially endtidal co2, through capnography.
Study: NCT02878603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: • PE with plasma (e.g., fresh frozen plasma, solvent detergent/viral-inactivated plasma, cryosupernatant), • Corticosteroid treatment and • Use of other immunosuppressive agents (e.g., rituximab).
Study: NCT03965715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printing AFO, anterior AFO, off-the-shelf AFO
Description: Subjects wear different AFOs and performed gait analysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printing AFO, anterior AFO, off-the-shelf AFO
Description: Subjects wear different AFOs and performed gait analysis.
Study: NCT03180567

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Genetic Mutations
Description: By next generation sequencing

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genetic Mutations
Description: By next generation sequencing
Study: NCT02373579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acids
Description: study group, included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
Study: NCT02895932

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging
Description: Serotonin, Dopamine and Amyloid PET imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET imaging
Description: Serotonin, Dopamine and Amyloid PET imaging
Study: NCT04513639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early treatment of relapse with carfilzomib, dexamethasone, daratumumab
Description: Second line treatment will start at MRD reapperance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab
Description: Second line treatment will start at progressive disease
Study: NCT02754362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a proangiogenic factor which aids in tumor vessel formation.
Study: NCT02532283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
Study: NCT01139346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darinaparsin
Description: dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
Study: NCT02754362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a proangiogenic factor which aids in tumor vessel formation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a proangiogenic factor which aids in tumor vessel formation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine
Description: Vaccine of long synthetic peptides encoding T cell epitopes in tumor associated antigens.~Vaccine Consists of:~EGFRvIII peptide 100 mcg IL13Ralpha peptide 100 mcg EphA2 peptide 100 mcg Her2/neu peptide 100 mcg YKL-40 peptide 100 mcg
Study: NCT01150253

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L. paracasei fermented milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. paracasei fermented milk
Study: NCT01911702

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard fluidic resuscitation.
Description: Goals:~1. arterial pressure mean ≥ 65 mmHg or equal to the pre-operative~2. diuretic rhythm ≥ 1 ml / Kg / h~3. venous saturation in vena cava ≥ 70% or mixed venous saturation as Swan Ganz's catheter (SG) ≥ 65%~4. BE\> - 3~5. Central Venous Pression (PVC) ≥ 8 mmHg; for patients undergoing mechanical ventilation, this limit may be raised to 12-15 mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volemic small treatment
Description: Goals of the treatment:~1. arterial pressure mean ≥ 60 mmHg or ≥ 10% less than the preoperative values~2. diuretic rhythm ≥ 0.5 ml / kg / h~3. venous saturation in vena cava ≥ 60% or mixed venous saturation ≥ 55% by SG~4. BE\> - 5~5. PVC goal not necessary~To achieve the therapeutic goals set out above will be executed a volemic fill up to values of PVC ≤ 5 mmHg or at maximum values of 2 mmHg more the incoming If after proper filling the targets aren't yet achieved, the patient will begin infusion of vasoactive drugs following the practice of department. If after 12 hours of admission the water balance will be \> 10-15 ml / kg / h an infusion of furosemide should be initiated
Study: NCT02754362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine
Description: Vaccine of long synthetic peptides encoding T cell epitopes in tumor associated antigens.~Vaccine Consists of:~EGFRvIII peptide 100 mcg IL13Ralpha peptide 100 mcg EphA2 peptide 100 mcg Her2/neu peptide 100 mcg YKL-40 peptide 100 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC as immune adjuvant
Description: Poly-ICLC is a toll like receptor 3 agonist which directly activates dendritic cells and triggers natural killer cells to kill tumor cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC as immune adjuvant
Description: Poly-ICLC is a toll like receptor 3 agonist which directly activates dendritic cells and triggers natural killer cells to kill tumor cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin (KLH)
Description: Potent Immunogen used in vaccine approaches for a number of diseases including cancer, AIDS, and infectious diseases
Study: NCT03643549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib and Temozolomide Phase IB
Description: In the Phase IB of the study the following dose escalation of TMZ will be performed: The first cohort of 3 patients will receive 150 mg/m2 of IMP (TMZ) for 5 days q4w. If one patient in this cohort develops a dose limiting toxicity, another cohort of 3 patients will be treated at the same dose level until 2 or more patients in the group of 3-6 develop DLT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib and Temozolomide Phase II
Description: The patientes will be treated with the maximum recommended starting dose of Temozolomide and Bortezomib established in the IB phase of the study
Study: NCT03402074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group hypnosis
Description: 5 session of group hypnosis, each 90 minutes, to reduce subjective stress and increase relaxation. Additional auditapes of hypnosis sessions as hoemwork
Study: NCT00696007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin
Description: Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.~Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.~Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²

Intervention type: OTHER
Group type: OTHER
Intervention: Retrospective comparison
Description: 60 retrospective historical cohort group of subjects who have undergone a radical nephroureterectomy over the past five years
Study: NCT04711694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minfulness-based Intervention
Description: The proposed MBI is an adaptation from the Mindfulness Based Stress Reduction (MBSR) and Mindfulness based Cognitive Therapy (MBCT) programs to youth. This MBI consists of a total of twelve 90 minutes long sessions, the first 8 being the intervention per se and the last 4 a proposition to the transition to regular practice and a chance to better integrate mindfulness in daily life.~A theme regarding mindfulness is addressed in each session, through meditation practices and exercises. Between sessions, participants are invited to practice at home, using an application designed for this study (the MindApp), where participants can find the recorded practices. Investigators have access to participants' use of the meditation recordings and expect that these data will provide a more objective measure of the amount of home practice.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minfulness-based Intervention
Description: The proposed MBI is an adaptation from the Mindfulness Based Stress Reduction (MBSR) and Mindfulness based Cognitive Therapy (MBCT) programs to youth. This MBI consists of a total of twelve 90 minutes long sessions, the first 8 being the intervention per se and the last 4 a proposition to the transition to regular practice and a chance to better integrate mindfulness in daily life.~A theme regarding mindfulness is addressed in each session, through meditation practices and exercises. Between sessions, participants are invited to practice at home, using an application designed for this study (the MindApp), where participants can find the recorded practices. Investigators have access to participants' use of the meditation recordings and expect that these data will provide a more objective measure of the amount of home practice.
Study: NCT04516239

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA
Description: Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. For the THA, the standard techniques proposed by the manufacturer for insertion of the stem were followed. Neck sleeve adapters and three different prosthetic neck-shaft angles (125, 135, and 145) were available to adjust leg length and femoral offset with the large-diameter head THA system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HR
Description: Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. In the HR group, the capsulotomy was completed circumferentially, and the gluteus tendinous insertion on the femur was released in all men, but only when needed in women, to improve femur mobilization.
Study: NCT00227019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, IV over 10 minutes every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m²; IV over 10 minutes every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1000 micrograms, IM injection 1-2 weeks prior to treatment and repeated every 9 weeks until last dose of pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folate
Description: 350 to 1000 micrograms 1 week prior to treatment and 3 weeks after last pemetrexed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg; oral, twice a day at the following times: the day before, of and after each dose of pemetrexed
Study: NCT00625183

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenomethionine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02797860

Intervention type: DRUG
Intervention: Rocuronium
Description: comparison of onset time and duration of rocuronium using Train of Four watch

Intervention type: DRUG
Intervention: Rocuronium
Description: comparison of onset time and duration of rocuronium using Train of Four watch
Study: NCT00920413

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: vitamin C 500mg orally once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00202098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Variable ventilation
Description: Patients will be mechanically ventilated with Variable Ventilation (3 step with increased level of variability) and traditional CMV, for a total of 4 step. Each step lasts in 60 minutes. During this period the investigators will record the gas exchange parameters and the mechanics of the respiratory system.
Study: NCT02959333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAEC
Description: hAEC: human amniotic epithelial cells
Study: NCT00889915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate transdermal system
Description: Not specified in protocol; determined by local standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine dimesylate
Description: Not specified in protocol; determined by local standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osmotic-release oral system methylphenidate (OROS MPH)
Description: Not specified in protocol; determined by local standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixed amphetamine salts extended release
Description: Not specified in protocol; determined by local standard of care.
Study: NCT01850394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Inject tranexamic acid solution intra-articularly after fascia closure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Inject tranexamic acid solution intra-articularly after fascia closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: Use physiologic saline for mixing with tranexamic acid or use alone in placebo group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiologic saline
Description: Use physiologic saline for mixing with tranexamic acid or use alone in placebo group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiologic saline
Description: Use physiologic saline for mixing with tranexamic acid or use alone in placebo group